FDA Approves Oral PCSK9 Inhibitor for Cholesterol Reduction

Why it matters locally: This FDA approval provides a new oral treatment option for individuals in Hawaii managing hypercholesterolemia, potentially improving access to care given the high prevalence of related health conditions in the state. Local healthcare providers will be able to prescribe Lipfendra as an additional tool for patients.

---

WASHINGTON – The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide) for the reduction of low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. This medication represents the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Doctors will prescribe Lipfendra as an addition to diet and exercise regimens. The FDA's decision provides a new treatment option for individuals working to manage their cholesterol levels.